Obesity and metabolic disease ran through the week, from CHMP backing for Lilly's oral orforglipron to a terminated GLP-1 trial at Verdiva and a cool reception for Biomea's Phase 1 data, alongside three financings and an FDA safety alert on a mitral-valve device.
Read article →This week's biopharma news was led by four FDA drug approvals, a run of retinal and ophthalmic readouts, and a cluster of programme failures: argenx in Sjogren's, ArriVent in lung cancer, Nuvig in CIDP and Caribou winding down its CAR-T pipeline.
Read article →This week's biopharma news was led by a crowded obesity field, immune-reset readouts in lupus and myasthenia gravis, and four reversals: a discontinued candidate, a withdrawn filing, a revoked authorization and an ended collaboration.
Read article →91 tracked developments across 12 disease areas, 14-18 September 2026: approvals, late-stage data, deals and pipeline changes, each with what it means for the competitive landscape.
Read article →This week's biopharma news was led by oncology readouts, regulatory momentum in rare disease, and a handful of notable pipeline setbacks.
Read article →Approvals, Phase 3 Inflection Points, and Cell-Therapy Safety Signals
Read article →